The ADVENT trial's designation as a frontline clinical trial means that CORE-NK cells are being tested in conjunction with the SOC at the earliest stage of treatment for newly diagnosed AML patients. This sets it apart from other studies in relapsed or refractory-disease-only contexts... where other therapies can only be tested on the sickest of sick.
Not only does this trial signify an effort to integrate immunotherapies early in treatment, rather than reserving them just for relapsed/refractory settings, but its a space where our technology doesn't have to compete against chemotherapy in terms of market share or against the ravages it inflicts on patients' immune systems.
What I am a little confused about is why the third bullet "Ph. 1B ADVENT AML Frontline"in the 2024 Deliverables even exists. We know that the trial is frontline. Does it suggest then that we will receive an announcement about the recruitment of each of the risk-stratification cohorts, OR an ann about the trial design (dose levels specific to each cohort) followed by a separate ann on the first cohort data readout?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)